Salim Yazji insider trades: Oncternal Therapeutics (ONCT) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Salim reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 14, 2023 | ONCT | ↑ Buy | 25,000 | $0.29 | $7K | Direct | Apr 14, 2023 (0d) |
| Jan 27, 2022 | ONCT | ↑ Buy | 10,000 | $1.69 | $17K | Direct | Jan 31, 2022 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Salim Yazji's insider trades
Salim Yazji is Chief Medical Officer at Oncternal Therapeutics (ONCT). Since Jan 27, 2022, Salim has reported 2 open-market purchases worth $24K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (6 filings), shares withheld for taxes (3 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ONCT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.